Optimum TV Interview

Check out our CEO Jason Loveridge as he speaks with Stephen Adams of Optimum Strategic Communications in the latest episode of optimumtv 📺!

To achieve this, please click here

4SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby)

We are pleased to announce that the European Medicines Agency (EMA) has accepted 4SC's Marketing Authorisation Application (MAA) for lead candidate resminostat (Kinselby).

To read more

KOL Webinar

Please watch a presentation and Q&A session with Dr. Susanne Danhauser-Riedl, 4SC’s Chief Medical Officer, and experts Professor Dr. Rudolf Stadler and Professor Julia Scarisbrick, on the landmark positive RESMAIN study data that could significantly change current clinical practice in the treatment of advanced CTCL.

To watch Video

Innovative drugs for cancer patients

Our values, experience and commitment are the keys to developing better drugs for patients with cancer.

Learn more about our clinical trials

A pioneering spirit is our driving force

We are curious by nature and seek to address fundamental questions in cancer biology which we hope will result in better drugs for patients with cancer.

Learn more about our products

One team – one goal

We are united by our shared values, and a sense of fairness and curiosity.

Learn more about 4SC

Success secures our future

Experience and expertise lead to better decision making, informative data and peer and patient recognition – the foundation for our success.

Learn more about our perspectives

Transparency for partners

Continuous exchange and open communication create value and long-standing partnerships.

Learn more about our partners

News

11. Sep 2024

4SC AG resolves to issue new shares with expected proceeds of approx. EUR 4 million

08. Aug 2024

4SC announces Half-Year Report 2024 and provides update

01. Aug 2024

4SC AG: Conference call to be hosted on 8 August 2024 to present the H1 report 2024

All news

Events

Currently there are no events.

All events

4SC AG: Developing innovative drugs for cancer patients

Headquartered in Planegg-Martinsried near Munich/Germany, 4SC is an innovative biopharmaceutical company with a strong focus on product development in oncology.

We develop novel small molecule drugs for the treatment of cancer in indications with a high unmet medical need and significant economic potential.

We wish to offer affected patients treatment options that are more effective and better tolerated to provide a better quality of life.

Our product pipeline comprises promising drug programs at various stages of clinical development. We are focusing on fields of research that contribute to the development and persistence of cancer.